{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-060406","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2022-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.986527+00:00","generated_at":"2026-06-23T06:19:41.703850+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silo Pharma closes $5.75M public offering at $5/share, uplists to Nasdaq; appoints new CFO and director","bullets":["Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.","Common stock began trading on Nasdaq Capital Market under ticker SILO on September 27, 2022.","CFO Eric Weisblum resigned; remains CEO and President. Daniel Ryweck appointed CFO with $42,000 annual base salary.","Board appointed Dr. Jeff Pavell as director and chair of nominating and corporate governance committee.","Proceeds to fund product development, marketing, working capital, and potential acquisitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-060406","json":"https://secwatch.observer/filing/0001213900-22-060406.json","markdown":"https://secwatch.observer/filing/0001213900-22-060406.md","text":"https://secwatch.observer/filing/0001213900-22-060406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/ea166467-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:19:41.703850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73fd218037","claim":"Daniel Ryweck was appointed as Chief Financial Officer at Silo Pharma, Inc..","evidence_excerpt":"On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b662e3df51","claim":"Eric Weisblum resigned as Chief Financial Officer at Silo Pharma, Inc..","evidence_excerpt":"On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fea89e4033","claim":"Jeff Pavell was appointed as Director at Silo Pharma, Inc..","evidence_excerpt":"On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}